|Mr. Uday V. Baldota||CEO & Director||N/A||N/A||1970|
|Mr. Mariano Balaguer||CFO, Chief Accounting Officer & VP||N/A||N/A||1973|
|Mr. Itamar Karsenti||VP & Head of Global Operations||N/A||N/A||1972|
|Mr. Itzik Baruch||VP of Technical Services||N/A||N/A||1963|
|Dr. Roman Kaplan Ph.D.||VP of Scientific and Technical Compliance Mang.||N/A||N/A||1947|
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. It also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. The company offers its products primarily in the areas of topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, anti-inflammatory, and other therapeutic categories. The company distributes and sells its products directly to wholesalers, retail drug store chains, mass merchandisers, grocery chains, and other direct purchasers and customers, as well as healthcare institutions and private pharmacies. The company was founded in 1959 and is based in Haifa Bay, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Alkaloida Chemical Company Exclusive Group Ltd.
Taro Pharmaceutical Industries Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.